Vigil Neuroscience Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vigil Neuroscience Inc 's ROA in the second quarter of 2025?
Vigil Neuroscience Inc recorded a cumulative net loss of $-92 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -88.86%.

However, within the Healthcare sector 740 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 4374, from total ROA ranking in the first quarter of 2025 at 4384.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	-7.52 %	-3.63 %	-17.31 %	-17.34 %	-40.52 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-92	-87	-84	-83	-84
Return On Assets (TTM)	-88.86 %	-82.22 %	-79.12 %	-73.8 %	-71.01 %
VIGL's Total Ranking	# 4374	# 4384	# 5017	# 4413	# 4444
Total Assets (TTM) in million	87	107	104	117	94
Seq. Total Assets Change	-19.08 %	3.12 %	-11.28 %	24.92 %	-15.68 %
Seq. Net Income Change	-	-	-	-	-

VIGL's 5 Years Annual ROA >> Back to VIGL Management Effectiveness >> Compare VIGL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 118
Sector	# 741
Overall	# 4319

Return On Assets Statistics
High	Average	Low
-36.59 %	-56.12 %	-83.25 %
(Dec 31 2022)		(Jun 30 2025)

Financial Statements
Vigil Neuroscience Inc 's Assets	$ 87 million	VIGL's Balance sheet
Vigil Neuroscience Inc 's Income	$ -27 million	Quarterly VIGL's Income Statement
VIGL's Income by Division		See VIGL's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY	FY
Y / Y Total Assets Change	-17.31 %	-37.3 %	-	-	-
Total Assets in million	104	126	200	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-84	-83	-68	0	0
Annual Return On Assets	-81.09 %	-65.77 %	-34.09 %	-	-

VIGL's 5 Years Annual ROA >> Back to VIGL Management Effectiveness >> Compare VIGL ROA to its Competitors

More Return On Assets Ratios
VIGL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VIGL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VIGL's Competitors
Subscribers only: Roa for Vigil Neuroscience Inc 's Suppliers
Subscribers only: Return On Assets for VIGL's Customers

You may also want to know
VIGL's Roi	VIGL's Inventory Turnover Ratio	VIGL's Growth Rates	VIGL's Dividend Comparisons
	VIGL's Profitability Ratios	VIGL's Asset Turnover Ratio	VIGL's Dividend Growth
VIGL's Roe	VIGL's Valuation Ratios	VIGL's Financial Strength Ratios	VIGL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:41:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.